相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Charlson Comorbidity Index: A Critical Review of Clinimetric Properties
Mary E. Charlson et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2022)
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna et al.
LANCET RHEUMATOLOGY (2022)
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Michael Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
Sonia Boyer-Suavet et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
Pierre Charles et al.
ANNALS OF INTERNAL MEDICINE (2020)
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Rona M. Smith et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Serious safety events in rituximab-treated multiple sclerosis and related disorders
Brandi L. Vollmer et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Jacques-Eric Gottenberg et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection
Julien Henry et al.
RHEUMATOLOGY (2018)
Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016
Sarah Wongseelashote et al.
INTERNAL MEDICINE JOURNAL (2018)
Long-term persistence with rituximab in patients with rheumatoid arthritis
Alexander G. S. Oldroyd et al.
RHEUMATOLOGY (2018)
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
Geetabali Sircar et al.
RHEUMATOLOGY (2018)
Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study
G. Boleto et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides
Benjamin Terrier et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome
Simon J. Bowman et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies
Jon Thorkell Einarsson et al.
CLINICAL RHEUMATOLOGY (2017)
Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study
Ilias Lazarou et al.
JOINT BONE SPINE (2016)
Off-label use of rituximab for systemic lupus erythematosus in Europe
Monica Ryden-Aulin et al.
LUPUS SCIENCE & MEDICINE (2016)
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Treatment of Primary Sjogren Syndrome With Rituximab A Randomized Trial
Valerie Devauchelle-Pensec et al.
ANNALS OF INTERNAL MEDICINE (2014)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis A Randomized, Placebo-Phase Trial
Chester V. Oddis et al.
ARTHRITIS AND RHEUMATISM (2013)
Available evidence and outcome of off-label use of rituximab in clinical practice
I. Danes et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Experience with low-dose rituximab in off-label indications at two tertiary hospitals
J. Chay et al.
INTERNAL MEDICINE JOURNAL (2013)
Prospective data collection of off-label use of rituximab in Australian public hospitals
K. O'Connor et al.
INTERNAL MEDICINE JOURNAL (2013)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label
Candido Diaz-Lagares et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Hans-Peter Tony et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
R. M. Thurlings et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Off-label use of rituximab in a tertiary Queensland hospital
S. J. Butterly et al.
INTERNAL MEDICINE JOURNAL (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales
R. Sharma et al.
INTERNAL MEDICINE JOURNAL (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
分享论文
